Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics by Lovera, S et al.
RESEARCH ARTICLE
Towards a Molecular Understanding of the
Link between Imatinib Resistance and Kinase
Conformational Dynamics
Silvia Lovera1, Maria Morando2, Encarna Pucheta-Martinez1, Jorge L. Martinez-
Torrecuadrada3, Giorgio Saladino1,4*, Francesco L. Gervasio1,4*
1Department of Chemistry, University College London, London, United Kingdom, 2 Center of Technological
Development in Health, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil, 3 Proteomics Core Unit,
Spanish National Cancer Research Centre (CNIO), Madrid, Spain, 4 Institute of Structural and Molecular
Biology, University College London, London, United Kingdom
* g.saladino@ucl.ac.uk (GS); f.l.gervasio@ucl.ac.uk (FLG)
Abstract
Due to its inhibition of the Abl kinase domain in the BCR-ABL fusion protein, imatinib is
strikingly effective in the initial stage of chronic myeloid leukemia with more than 90% of
the patients showing complete remission. However, as in the case of most targeted anti-
cancer therapies, the emergence of drug resistance is a serious concern. Several drug-
resistant mutations affecting the catalytic domain of Abl and other tyrosine kinases are
now known. But, despite their importance and the adverse effect that they have on the
prognosis of the cancer patients harboring them, the molecular mechanism of these muta-
tions is still debated. Here by using long molecular dynamics simulations and large-scale
free energy calculations complemented by in vitromutagenesis and microcalorimetry
experiments, we model the effect of several widespread drug-resistant mutations of Abl.
By comparing the conformational free energy landscape of the mutants with those of the
wild-type tyrosine kinases we clarify their mode of action. It involves significant and com-
plex changes in the inactive-to-active dynamics and entropy/enthalpy balance of two func-
tional elements: the activation-loop and the conserved DFG motif. What is more the T315I
gatekeeper mutant has a significant impact on the binding mechanism itself and on the
binding kinetics.
Author Summary
Imatinib remains the most important and studied anti-cancer drug for cancer therapy in
its new paradigm. Due to its inhibition of the Abl kinase domain, imatinib is strikingly
effective in the initial stage of chronic myeloid leukemia with more than 90% of the
patients showing a complete remission. However, the emergence of drug resistance is a
serious concern. Here, we investigate the molecular mechanism of drug-resistant muta-
tions which, despite the importance and the adverse effect on cancer patients prognosis, is
still debated. Our extensive molecular simulations and free energy calculations are
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consistent with an allosteric effect of the single-point drug-resistance-causing mutations
on the conformational dynamics. Two partially independent conformational changes play
a role. Our findings might help the design of anti-cancer therapies to overcome drug resis-
tance and be used to predict the clinical relevance of new drug-resistant mutants found by
genetic screenings of tumor samples.
Introduction
The revolutionary discovery of the potent anticancer drug imatinib (Gleevec, 2001) [1] had a
huge impact on cancer therapy. This drug has a striking efficacy in the early stages of chronic
myeloid leukemia (CML), with 90% of patients showing remission [2, 3]. Imatinib targets the
Abl tyrosine kinase (TK), constitutively active in CML due to a chromosomal translocation [4].
Unfortunately, most patients in an advanced stage of the disease suffer from relapse due to the
onset of drug-resistance [5]. Even if, next-generation kinase inhibitors (KIs) are available, or in
clinical trials [6], their efficacy might also be affected by drug resistance responses. Among dif-
ferent mechanisms, the development of resistance-inducing mutations is the most relevant in
tyrosine kinases [6]. Mutations occur in highly conserved positions on the protein [7], fre-
quently shared by several kinases [8], suggesting a conserved kinome-wide mechanism. Unfor-
tunately, the molecular mechanism of mutation-mediated resistance are only partially
understood. In the case of the widely studied “gatekeeper”mutant, found in several TKs
(T315I in Abl) [9], three mechanisms have been proposed. The direct one involves the abro-
gation of a crucial hydrogen bond formed by imatinib. A second hypothesis posits that the
observed shift towards the active form, which was reported in Abl and several other TK bearing
the gatekeeper mutation, would allow the natural substrate ATP to outcompete the inhibitors.
[10–13] Very recently, a third mechanism has been proposed for Abl T315I whereby the sup-
pression of an induced fit effect involving the p-loop would be responsible for the decreased
binding affinity of imatinib. [14] It is probable that the gate-keeper mutations have a combined
effect on the binding of inhibitors, changing their binding mode and affecting at the same time
the conformational changes [10, 11]. The importance of the conformational changes in the
mode of action of drug-resistant mutations [15, 16] is also confirmed by the fact that many of
them are far away from the binding site (Fig 1), and thus act allosterically by disfavoring the
drug-binding conformation and favoring active form [8, 17–19]. The link between conforma-
tional changes and allosteric regulation in TKs is well established. For instance, in the case of
Src (a close homologue of Abl) the gatekeeper mutation has been shown to allosterically affect
remote regulatory motifs [20].
Indeed, TKs can exist in a dynamic equilibrium between multiple conformations [21–23],
differing by the conformation of the “activation loop” (A-loop), of the conserved DFG motif
and of the αC-helix (Fig 1). While the features of the active, catalytically-competent, state are
shared among different TKs, and include an A-loop in an extended (“open”) conformation,
inactive conformations can be multiple and highly diverse, all sharing an (at least partially)
“closed” A-loop. Type II inhibitors, as imatinib, target a particular inactive conformation,
known as “DFG-out”, where the aspartate is flipped, taking the place of the phenylalanine and
pointing out of the ATP binding site [24] and opening an adjacent “allosteric” pocket. When
both the DFG is in the ‘out’ conformation and the A-loop is not fully extended, the drug can
enter the cavity and adopt a bridge position above the DFG, occupying both the catalytic site
and the allosteric pocket [25]. The DFG-out conformation has been observed in many kinases
but, despite a common binding mode, imatinib binds strongly only to some of them [26]. In
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contrast to the induced-fit mechanism proposed for Abl, free energy calculations performed
with different and independent approaches on several TKs are consistent with a conforma-
tional selection mechanism [23, 27, 28]. Indeed, the different affinity to Abl and Src can be
explained by the thermodynamic penalty to adopt the drug-binding “DFG-out” conformation
[29]. Our simulations on Abl and Src also revealed a correlation between the flexibility of spe-
cific functionally-relevant structural elements and the DFG-out penalty [29].
To investigate the molecular mechanism of drug-resistant mutations, and whether or not
changes in the conformational landscape, have a role in it, here we performed enhanced-sam-
pling atomistic molecular dynamics (MD) simulations and free energy calculations on a pool
of wild-type (WT) TKs for which imatinib has various strengths (IC50), and several Abl Imati-
nib-resistant mutants. In most drug resistant mutants we find extensive changes in the confor-
mational free energy landscapes associated with two functionally-important conformational
changes: the DFG-flip and the closed to open A-loop switch. The changes between the relative
free energies of the active (DFG-in, extended A-loop) and inactive (DFG-out, closed A-loop)
states are in the main due to entropic contributions arising from the fast (sub-μs) dynamics of
proximal structural elements. It is thus not surprising that we find a correlation between the
sub-μs flexibility of specific structural elements in the active state and drug resistance. Indeed,
altering the sub-μs dynamics has an effect on the binding of Imatinib, as also shown by muta-
genesis and calorimetry experiments. The gatekeeper mutant T315I is a notable exception, as it
affects both the binding mechanism itself and the conformation of the A-loop equilibrium. To
the best of our knowledge this is the most in-depth computational study addressing the molec-
ular roots of resistant mutants of Abl.
Fig 1. Abl structure and location of drug-resistant mutations. The main structural features, including the
regions undergoing conformational changes are highlighted in different colors (a). On the right (b) imatinib
binding mode and the position of drug-resistant mutants are shown. The mutants with a “known”mechanism
of action are depicted in green, those for which the mechanism is still unknown in red.
doi:10.1371/journal.pcbi.1004578.g001
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Materials and Methods
Molecular Dynamics Simulations
The kinase structures were retrieved from the Protein Data Bank (PDB entries 2G1T, 2SRC,
1PKG, 3KMM, 2WGJ and 2ITW). Missing residues were added using the software Modeller
[30], according to the respective Uniprot sequences. We used the Amber99SB-ILDN [31, 32]
force field, including backbone corrections by Hummer and Best [33], with explicit TIP3P [34]
water molecules. The unbiased MD simulations were carried out with the ACEMD program
[35] running on GPUs. The systems were minimized with 10000 steps of conjugated gradient
and equilibrated in the isothermal-isobaric (NPT) ensemble for 10 ns, using a Berendsen baro-
stat at 1 atm. The temperature was kept at 305 K by a Langevin thermostat. A 400 ns produc-
tion run was carried out for all the systems in the canonical (NVT) ensemble. The runs for Abl,
Src and Kit were extended to a total length of 1 μs in both the DFG-in and DFG-out conforma-
tions. The simulations of the five Abl mutants (G250E, E279K, H396P, E450K and T315I) were
carried out with the same setup in both the DFG-in and DFG-out conformation, after mutating
in-silico the respective residue in the Abl structure. To capture the sub-μs dynamics, the RMSF
of the Cα were averaged on 30ns non-overlapping windows after discarding the first 100ns of
each run. We also compared the diffusion in the space described by the first two principal com-
ponent analysis vectors (see S9 Fig).
Since the conformational changes of TKs take place on time scales longer than those accessi-
ble by standard MD simulations, here we used a combination of enhanced sampling
approaches. Parallel Tempering—Well Tempered Metadynamics [36, 37] in the well tempered
ensemble (WTE) [38, 39] (PTmetaD) was chosen due to its proven ability to fully converge
complex conformational free energy surfaces such as those relevant in kinases (including the
DFG-flip). Indeed, the PTmetaD approach (both in the standard and WTE variants) has
already successfully used to study the conformational dynamics and its associated free energy
landscape in many kinases [12, 13, 29, 40, 41] and other flexible proteins [39, 42]. PTmetaD
was performed using the software Gromacs 4.5 [43] and the PLUMED plugin [44], using an
integration step of 2 fs. The particle mesh Ewald algorithm was used for electrostatic interac-
tions. Temperature coupling was done with the V-rescale algorithm [45]. The WTE allowed
the use of a reduced number of replicas compared to standard PTMetaD [12, 39]. An average
exchange probability of 24% was obtained using 5 replicas in the temperature range 305–400
K. We used the same four collective variables (CVs) that were used to reconstruct the free
energy surface (FES) associated with the DFG flip in Src and Abl [29].
They are shown in S6 Fig and defined in the following (SRC numbering): CV1 is the dis-
tance between the centre of mass of Asp404 (DFG motif) and Lys295. CV2 is the distance
between the centre of mass of Phe405 and the Cβ of Ile293. CV3, is a function of 3 dihedral angles
f(ϕ404, ψ405, ψ408) ranging from 3, when the three dihedral arguments correspond to the
DFG-Asp-in position, to 0, when they are in the DFG-Asp-out conformation. CV4 is the dis-
tance between the centre of mass of residues Asn381, . . ., His384 and residues Ala408, . . ., Ile411
of the activation loop, known to form a β-sheet in the active conformation. The height of the
Gaussians was set at 2.0 kJ/mol with a deposition rate of 1/2000 steps and a bias factor of 5.
The Gaussian width used for the CVs was 0.1 for the dihedral similarity (CV3) and 0.3 Å for all
the others.
A minimum of 400 ns of sampling per replica in the NVT ensemble were needed to reach
full convergence of the free energy. In the case of G250E and T315I, as the convergence was
slower than in the other cases, we performed more than 600 ns and 1200 ns of sampling per
replica, respectively. The total sampling time amounted to more than 14 μs across all mutants.
The free energy surface reconstruction was obtained from the PT-metaD-WTE by reweighting
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the fixed potential energy bias and using two independent approaches: integrating the bias or
using the time independent estimator of Ref. [46]. The convergence of the free energy recon-
struction was monitored by integrating the cumulative added bias as a function of time (50 ns
intervals) and comparing the reconstruction to that obtained by the time-independent estima-
tor (as shown in S11, S14–S18 Figs). Changes of all the CVs used were also monitored to guar-
antee that the system diffuses freely in the CV space and is able to visit all the basins several
times (see S12 Fig).
The FES were also reprojected as a function of two other CVs describing the conformational
change of the A-loop from open to closed. Two path collective variables [47] were built by
using the open and closed crystallographic structures of Src (CV1) and Abl (CV2). The
reweight was performed by using our python implementation of the approach of Ref. [46]
(available on our homepage: https://www.ucl.ac.uk/chemistry/research/group_pages/prot_
dynamics/. The entropic contribution to the DFG-in DFG-out free energy difference was com-
puted by linear fitting of the free energy differences as a function of temperature. It has been
shown that this approach is more accurate than competing ones. [48]. We also tested the
robustness of the estimate with respect to the range of temperatures on both standard PT and
WTE-PT (see S8 Fig).
The drug binding free energy surface was calculated using metadynamics with the same
software described above. The General Amber Force Field (GAFF) was used for the ligand. The
ligand charges were calculated at the HF level using a 631-G basis set with the Gaussian03
[49] package. QM-level torsional scans with a step of 10 degrees were carried out for the ca-ca-
n-c and ca-ca-c3-n3 dihedrals which appeared to have wrong torsional profiles. The profiles
with the GAFF force field in vacuum were then fitted to the QM ones to refine the dihedral
parameters. As customary in the case of ligand binding [50, 51], we performed a preliminary
metadynamics run using sub-optimal geometrical CV to obtain an initial pathway for the setup
of the path collective variables (PCV) [47]. We selected 23 frames from the lowest free energy
path obtained in the preliminary run and optimized this initial guess using the methodology
described by Branduardi et al. [47]. To take into account possible rearrangements, we included
the Cα atoms of the A-loop and of the αC-helix in the definition of the PCVs. The 2 PCVs s
and z were used to run a 300 ns metadynamics. The height of the Gaussians was set at 2.0 kJ/
mol with a deposition rate of 1/2000 steps and a bias factor of 10. The Gaussian width used for
the CVs was 0.1 for s and 0.003 for z. The free energy corresponding to the last leg of the
unbinding mechanism (from the external binding pose to a fully solvated state) was computed
again by using Well-tempered metadynamics following the approach of Ref. [52].
Mutagenesis and ITC Measurements
Src was expressed and purified following the procedure detailed in Ref. [53]. For the first two
mutants, an auto-induction protocol was used to reach a good bacterial expression. Thermody-
namic binding parameters for the association of imatinib to Src wild type and to the designed
mutants were acquired using a VP-ITC microcalorimeter (MicroCal Inc.). The sample solution
consisted of 2 ml 0.1 mM protein in MES buffer (pH 6.5) supplemented with 2% DMSO. The
ligand solution consisted of 2 ml 1.6 mM imatinib in MES buffer (pH 6.5) with 2% DMSO.
Both solutions were degassed for 5 minutes under vacuum. Titrations were conducted at 30°C,
consisted of a first control injection of 1 μl followed by 37 injections of 8 μl over 16s, each
spaced by an equilibration period of 480s. The samples were stirred at 266 rpm. Raw data were
collected and corrected for ligand heats of dilution. A one site binding model was assumed and
data were fit using MicroCal Origin software (version 7.0). All experiments were repeated in
triplicate.
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Results and Discussion
We ran MD simulations on wild-type (WT) Abl, five clinically-reported drug-resistant
mutants of Abl and five WT tyrosine kinases (see Table 1) [29].
The aim is to assess if there is a correlation between the changes in sub-μs dynamics of the
TK structure (both in WT proteins and drug-resistant mutants) and the binding affinity of
imatinib. We probed the changes in sub-μs dynamics by comparing the root mean square fluc-
tuations (RMSF) of the Cα averaged over 30ns-long time windows. Among the most common
drug-resistant Abl mutants found in relapsing leukemia patients, we selected the gatekeeper
mutant (T315I) and four others far from the binding site (allosteric) having a strong impact on
imatinib binding (higher IC50 values, see Table 1) [16, 17, 54]. Apart from the widely discussed
gatekeeper mutant (T315I), the mechanism of resistance of the others is completely unknown.
In addition to Abl and its mutants, we selected a pool of homologous tyrosine kinases that,
while sharing the same imatinib binding mode, are inhibited by it with varying strength (see
Table 1) [5, 55–59].
The RMSFs (Fig 2) show that all the Abl mutants and the imatinib weak-binders TKs (Src,
Met and EGFR) are more rigid than WT Abl [29]. The regions most affected are the function-
ally-relevant regions of the N-lobe (p-loop, αC-helix and the β3-αC loop), the A-loop and, to a
lesser extent, the αG-helix, whose flexibility profiles are more “Src-like” [29]. An analysis of the
diffusion of the dynamics in the space defined by the first two principal component vectors of
Abl is also consistent with the rigidification of the mutants (see S9 Fig).
The DFG-out states, with the notable exception of G250E and T315I, are even more rigid,
indicating a probable entropic penalty with respect to the DFG-in states (see S7 Fig). The β3-
αC loop, which is known to play a role in the allosteric activation of Abl by the SH2 domain
[40, 60] is the most affected element.
The A-loop is more rigid in most mutants and in all the weak-binders group (Src, Met and
EGFR), while it is comparatively more flexible in the strong imatinib binders (Abl, Kit and
Lck). A-loop flexibility and IC50 are anti-correlated (Table 1). Finally, the αG-helix, an hotspot
for allosteric regulation in TKs [20, 61], is very flexible in the weak-binding group and in
E279K resistant mutant (see S2 Fig) and can experience unique conformational changes (see
S2 Fig). The clinical drug-resistant mutants of Abl [16] are prevalently located in regions of the
structure whose flexibility varies across weak and strong-binding TKs (see S1 Fig). This should
not be surprising, as the observed flexibility changes affect regions that are either directly
Table 1. RMSF of the A-loop region and IC50 values of imatinib for the studied tyrosine kinases and the
designed triple mutants of Src.
TK A-loop RMSF (Å) IC50 (μM)
Abl 4.2 0.037 [58]
E450K 4.85 2.3 [16]
T315I 2.5 6.4 [59]
H396P 2.15 9 [17]
E279K 2.6 9.9 [16]
G250E 1.8 >20 [16, 54]
Kit 5.5 0.3 [55]
Lck 3.2 9 [56]
Met 2.6 >100 [5]
EGFR 2.5 >100 [57]
Src 2 >100 [5, 57]
doi:10.1371/journal.pcbi.1004578.t001
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Fig 2. Root mean square fluctuation analysis of TKs and Abl resistant mutants. (a) RMSF of Abl and Src. Fluctuations of the N-lobe (left) and of the A-
loop (right) for the Abl mutants (b). and the TKs (c). Shades of red and blue identify strong and weak binders, respectively. Dotted lines are used for clarity.
doi:10.1371/journal.pcbi.1004578.g002
The Link between Imatinib Resistance and Kinase Dynamics
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involved in the binding of type II inhibitors (the DFG-motif, A-loop [25] and p-loop. [62], see
S1 Fig)) or allosterically connected to the former (αC-helix, αG-helix, β3-αC loop) [20, 40].
Thus, the change in the sub-μs dynamics of these regions could affect the entropic contribution
to the relative stability of the inactive and active states, in turn decreasing the binding affinity
of imatinib and other type II inhibitors that bind to an inactive state.
Site-Directed Mutagenesis
To understand whether inducing a change in the flexibility of relevant structural motifs is suffi-
cient to increase the drug sensitivity, we designed a number of Src KD mutants and measured
the changes in Kd.
We engineered mutations in four different locations, the P-loop (Q275), the β3-αC loop
(P299) the A-loop (Q420) and the αG-helix (V461), to the equivalent residues in Abl and Lck.
The residues to be substituted were chosen in the functionally-relevant regions showing a
major variation in the sub-μs dynamics, between the weak and strong imatinib binders. We
first performed MD simulations and compared the flexibility of various mutants to that of Src
WT. Based on the RMSF we choose three candidates for the experiments. The first bears
Q275A, P299Q and Q420E substitutions (Src to Lck), the second Q275G, P299E and Q420A
(Src to Abl) and a third one with Q275A, P299Q and V461S (Src to Abl).
The RMSF shows an increased flexibility in the N-lobe (p-loop, β3-αC loop and αC helix)
compared to Src WT (see S3 Fig). For the mutant Q275G/P299E/Q420A, also an increase in A-
loop flexibility was identified. In the Q275G/P299E/V461S mutant was introduced a mutation
on the αG-helix, that has provoked a suppression of the fluctuations in this area, resembling
the αG-helix of Abl. The Kd appear to be anti-correlated with the RMSF of the A-loop
(Table 2). As a cross-validation, when a chimeric protein with the entire αC-helix of Abl was
produced, we observed a general suppression of the dynamics and an increased Kd of 14 μM.
At difference with previous studies reporting similar Kd [26], the mutated residues are far from
the binding site and do not interact with the drug.
Conformational Dynamics
If the correlation between changes in the sub-μs dynamics and imatinib affinity observed in the
MD simulations and validated by experiments is due to entropic effects it must be reflected in
the conformational free energy landscape (and in the entropic contribution to the relative sta-
bilities of the DFG-in and -out states). As discussed above, Imatinib binds to an inactive state
in which both the conformation of the DFG motif and that of the A-loop are important. In
non-phosphorylated TKs the active-like “open” state in which the A-loop is extended, is mar-
ginally populated [12, 63, 64]. The DFG-out inactive state has a significant thermodynamic
penalty and (according to the observed changes in the sub-μs dynamics) is in most cases
Table 2. Kd for the Src mutants, Abl and SrcWT. The RMSF values have been averaged fromMD
simulations.
Protein A-loop RMSF (Å) Kd (μM)
Abl WT 4.2 0.08 [26]
Q275G/P299E/V461S 1.4 6.2
Q275G/P299E/Q420A 2.5 7.3
Q275A/P299Q/Q420E 1.8 8.5
Src WT 2 12
αC chimera 0.3 14
doi:10.1371/journal.pcbi.1004578.t002
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entropically disfavored. In both inactive states the delicate balance between entropic and
enthalpic contributions are crucial in defining their stability with respect to the open, DFG-in
active state. This balance can be easily upset by drug-resistant mutations either directly or
through the allosteric network. Thus a mutation affecting the entropy / enthalpy balance of the
active and inactive states could easily shift the kinase towards active state, decreasing the bind-
ing affinity of type II inhibitors. Indeed, the stabilization of the active (extended A-loop) con-
formation has been experimentally observed for many TK gatekeeper mutants (including Abl
T315I) [10, 11, 13, 65].
To further investigate this issue, we performed large-scale multiple-replica PT-MetaD simu-
lations and computed the fully converged conformational free energy landscape associated
with the DFG-flip of the five drug-resistant mutants. In Fig 3 we report the FES projected as a
function of two collective variables (CVs) that distinguish the DFG-in from the DFG-out state
[29], namely the distance between the DFG Asp404 and Lys295 and between the DFG Phe405
and Ile293 (Src numbering). As expected, for all mutants the global minimum of the FES corre-
sponds to the DFG-in state (basin “IN” in Fig 3). The mutants also explore the DFG-out state
(basin “OUT”), which in most cases corresponds to a well-defined metastable minimum. All
mutations alter significantly the conformational free energy landscape. The free energy penalty
Fig 3. Free energy of the DFG flip transition. Free energy surfaces of Abl, Src (adapted from Ref. [29]), and Abl drug-resistant mutants projected on the
distances between DFG Asp404 and Lys295 (CV1) and DFG Phe405 and Ile293 (Leu137 in Src) (CV2). The free energy minima corresponding to DFG-in
conformations are labeled “IN”, while “OUT” correspond to DFG-out conformations. The contour lines are drawn every 1 kcal/mol.
doi:10.1371/journal.pcbi.1004578.g003
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of the DFG-out state increases going from Abl WT and G250E (ΔG of 4 ± 0.5 kcal/mol) to
E450K (6 kcal/mol), H396P and E279K (7 ± 0.5 and 8 ± 0.5 kcal/mol). The gatekeeper T315I
and (to a lesser extent) G250E are significant exceptions as the ΔG associated to their DFG-flip
is very close to that of the WT. The increased thermodynamic penalty is due to a net entropic
loss of the DFG-out state, as shown in Table 3 (the DFG-in/-out free energy differences as a
function of the temperature are reported in S8 Fig). Again T315I and G250E are special cases
as there is an entropic gain for the DFG-out state. The entropic contributions to the DFG flip
are in excellent agreement with the observed changes in the sub-μs dynamics.
Indeed in H396P and E279K, where the A-loop is significantly more rigid, the flip has a
larger free energy penalty. In the cases of G250E and the T315I gatekeeper mutant the penalty
for the flip is comparable to that of the WT, and in agreement with the observed increased flex-
ibility of the N-lobe and A-loop in the DFG-out state, there is an entropic gain associated with
it. In both cases the DFG-out has a peculiar geometry where both Asp404 and Phe405 point out-
wards (S4 Fig) and an open active-like extended A-loop conformation is observed.
To quantify this aspect, we analyzed how the population of the “open” state is altered by the
mutations. We re-projected the free energy surfaces (FES) as a function of path variables [47]
describing the opening of the A-loop (Fig 4) with respect to Src (CV1) and Abl (CV2).
Abl, Src and E279K mainly populate semi-closed and closed conformations (basin B and C),
while G250E, T315I and to a lesser extent E450K, H396P show a minimum in correspondence of
the open A-loop (basin A, CV1< 6). The A-loop in these and other mutants tends to form a sec-
ond helix turn as in Src (S5 Fig). The residues involved are Asp391 to Ala395, which in the case of
H396P are right before the mutation. The formation of this helix has been shown to stabilize the
extended A-loop active state in TKs [10] and is also involved in the mechanism of oncogenic
mutations [7, 12]. The stabilization of the active state is known to weaken the binding of ATP-
competitive inhibitors to oncogenic mutants of EGFR [10, 12] and in the phosphorylated form of
Abl [25, 26]. In the case of T315I the observed stabilization of the active state is in agreement with
multiple experimental observations [10, 11, 13, 65].
Finally, we also observe a loss of structural integrity of the αC and αG helices in the DFG-
out state of most mutants (S4 Fig) in agreement with previous proposals stating that conforma-
tional transitions in kinases are accompanied by local unfolding of secondary structural ele-
ments [66, 67].
Binding Mechanism
Our results appear to be consistent with a significant impact of the resistant mutations on two
different conformational changes: the DFG flip, disfavoring the drug-binding conformation
(mainly mutants with rigidified A-loop and N-lobe), and the opening of the A-loop, possibly
Table 3. Entropy and Enthalpy contributions to the DFG-in DFG-out flip as obtained from the linear
regression of the Free Energy as a function of temperature.
TK ΔH (kcal/mol) TΔS (kcal/mol)
Abl -3.56 -8.01
E450K -2.66 -8.96
T315I 17.93 13.06
H396P -7.61 -14.51
E279K 1.02 6.9
G250E 43.69 39.79
Src -9.73 -15.28
doi:10.1371/journal.pcbi.1004578.t003
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favoring the locking of the kinase in an active form. However, from the simulations on the
unbound kinases, we cannot rule out an effect of the gatekeeper mutation on the proposed
“induced-fit”mechanism [14]. Indeed, the predicted ΔG associated to the DFG-flip of T315I,
which is very close to that of the WT, leaves two hypotheses open. Either the weaker binding of
imatinib is due to the observed stabilization of the extended A-loop active state, or to the sup-
pression of an induced fit effect, possibly acting on the p-loop conformation. To clarify this point
and shed more light on the binding mechanism itself, we have computed the binding free energy
of imatinib to Abl WT and Abl T315I along a physical association pathway. The use of such an
approach, albeit it is significantly more expensive than an “end-point” free energy calculation
(e.g. thermodynamic integration) has the advantage of reporting on free energy barriers and thus
on the binding and unbinding kinetics. As expected, the crystallographic binding pose corre-
sponds in both cases to the deepest minimum. Starting from that pose, the bidimensional (un-)
binding free energy profiles show a substantial difference in imatinib’s mechanisms of binding to
Abl WT and T315I (Fig 5). In theWT kinase the barrier to unbinding is lower (in agreement
with the observed differences in unbinding kinetics) and there is one main exit path. It is also
interesting to note that we find an “external binding pose” from which the inhibitor slides to its
final crystallographic binding pose. In the external binding pose the DFGmotif is already in the
“out” position. In T315I we observe two different unbinding / binding pathways (B’ and E, Fig 5
and S10 Fig) somewhat similar to previous proposals. [68] In both of them the p-loop has a sig-
nificant role. A pose similar to the external binding pose observed in the WT kinase is present
(C’ in Fig 5) but it is slightly shifted towards the αC helix and more stable than in the WT. Thus
Fig 4. Free energy of the A-loop opening. Free energy surfaces of Abl, Src, and drug-resistant mutants projected on the optimal path describing the
conformational change of the A-loop from open to closed in Src (CV1) and Abl (CV2). The free energy minima corresponding to an extended A-loop active-
like conformation are labeled “A”, “B” is used for A-loop semi-closed (inactive) conformations and “C” for fully closed A-loop conformations. The contour lines
are drawn every 1 kcal/mol.
doi:10.1371/journal.pcbi.1004578.g004
The Link between Imatinib Resistance and Kinase Dynamics
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004578 November 25, 2015 11 / 19
Fig 5. Free energy of imatinib (un-)binding to Abl and to the T315I ‘gatekeeper’ mutant. Free energy surfaces associated to the binding of imatinib to
WT Abl (top panel) and the T315I Abl “gatekeeper”mutant (bottom panel). The deepest energy minima correspond to the crystallographic binding pose and
are labeled A. On the way out, B and B’ correspond to an intermediate state (metastable in WT Abl) where imatinib is in between the DFG and the αC helix.
States C and C’ correspond to the “external binding pose”. Interestingly in Abl T315I there are two exit channels and both have an higher barrier than in the
WT. The contour lines are drawn every 2 kcal/mol.
doi:10.1371/journal.pcbi.1004578.g005
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the gain in free energy from the external binding pose to the final (crystallographic) pose is
lower, in agreement with the observed increase of the IC50. When the unbinding free energy
from C to a fully solvated state is accounted for (see S13 Fig), the overall free energy difference
from the unbound fully solvated state to the crystallographic pose is around 13 kcal ± 2 (the
larger convergence error is due to the algorithms used). When the free energy penalty of the
DFG flip (’ 4 kcal) is subtracted, we get 9 kcal ± 2, in agreement with the calorimetric and IC50
experimental data. It is thus clear that the effect of the T315I gatekeeper mutation is dual. It both
affects the binding mechanism and stabilizes the active, extended A-loop conformation.
Conclusions
We have studied the interplay between sub-μs dynamics and conformational dynamics in TKs,
and how these are influenced by drug-resistant mutations impacting Type-II inhibitors binding.
Overall, our simulations show that drug-resistant mutations have a significant effect on both the
sub-μs dynamics and the conformational free energy landscape. They affect the energy and the
population of the DFG-out inactive state and of the open A-loop active-like state. Since type II
inhibitors bind to the inactive kinase, a more accessible DFG-out state leads to a stronger binding
of imatinib and other type II inhibitors. On the contrary, a more populated active-like state, in
which the A-loop is elongated, increases the affinity towards ATP and disfavors type II inhibitors.
The selected drug-resistant mutants fall in two partially overlapping categories: those that
have a significantly higher free energy penalty for the DFG-out state (E279K, H396P) and
those (G250E, E450K, T315I) that populate the A-loop open active-like state. What is more the
T315I gatekeeper mutant has a significant impact on the binding mechanism itself and on the
binding kinetics.
The mutations affect the free energy differences associated to the conformational changes
mainly by changing the sub-μs dynamics and consequently the entropy / enthalpy balance of
the different states. Thus, relative short MD simulations, by revealing changes in the sub-μs
dynamics, might be used to predict the impact of new mutations on Imatinib resistance.
The important role played by the entropic penalty of the DFG-out state must also be kept in
mind when comparing low temperature and room temperature experiments. On the whole, we
characterized the mechanism of action of several drug-resistant mutants of Abl. We have
shown the link between fast and slow dynamics in these complex systems, providing a deeper
understanding of the thermodynamics, kinetics and allosteric regulation of type II inhibitor
binding TKs. In perspective, our results could help the design of fast and predictive computa-
tional approaches to predict the effect of yet unknown mutations of TKs.
Supporting Information
S1 Fig. Correlation between the structural position of resistant mutants of Abl and their
impact on imatinib IC50. (a) Binding modes of Type I and Type II kinase inhibitors. The ATP
binding site is divided into two sub regions, the ATP pocket (in pink) is occupied by both Type
I and II binders, while the allosteric pocket (in blue) is occupied just by Type II inhibitors, like
imatinib. The A-loop is colored in yellow and the DFG in green. (b) IC50 for each mutation of
Abl found in the work of Azam et al. and (c) corresponding position in the Abl structure. Muta-
tions localized in flexible regions are colored in orange, the ones lying in rigid regions in green.
(PDF)
S2 Fig. αG-helix dynamics and typical conformational changes. Fluctuations of the αG-helix
region for all the Abl drug-resistant mutants (a) and all the tyrosine kinases (b) under study.
Shades of red have been used to identify strong imatinib binders, while shades of blue identify
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weak binders. Solid and dotted lines have been used for clarity. (c,d) Different αG-helix confor-
mations peculiar of the Src kinase.
(PDF)
S3 Fig. Experimental data retrieved for the engineered mutants of Src. (a) RMSF of the N-
lobe (left panel) and the A-loop (right panel) regions for the engineered Src mutants. (b)
HisTrap and S75 columns chromatogram; the protein of interest is the more intense UV signal.
(c) Gels showing the obtained purified mutants. (d) Titration calorimetry experiments of Src
WT and of the designed mutants.
(PDF)
S4 Fig. Conformations of resistant mutants of Abl sampled during PTmetaD simulations.
DFG-out state of G250E (a) and E450K (b) with a peculiar out-out geometry. Unfolding event
of αC-helix and αG-helix for G250E (c), E279K (d), H396P (e,f) and E450K (g).
(PDF)
S5 Fig. Characteristic helix turn formation in the A-loop of the resistant mutants of Abl
and theory scheme. In the mutants the A-loop forms a second helix turn, characteristic of the
A-loop of Src, shown in (a). The A-loop conformations of the mutants have been shown as fol-
low: G250E (b), E279K (c), H396P (d), E450K (e) and T315I (f). A schematic representation of
the proposed resistance mechanism is shown in (g). The destabilization of the DFG-out inac-
tive state plays a prominent role.
(PNG)
S6 Fig. Collective variables (CVs) used in the PTmetaD-WTE calculations. Src numbering is
used throughout, with the exception of residue L317, that corresponds to residue I293 in Abl
(PDB:G1T numbering used). The dihedral angle combination f(ϕ404, ψ405, ψ408) (CV3) is
shown on the right.
(PDF)
S7 Fig. Root mean square fluctuation analysis of DFG-in and DFG-out conformations.
RMSF profiles of DFG-in (in orange) and DFG-out (in green) states for Src, Abl and the resis-
tant mutants of Abl.
(PDF)
S8 Fig. Entropic and enthalpic contributions to the DFG flip. Linear regressions of the
PTmetaD free energies as a function of temperature. Entropy and Enthalpy contributions have
been obtained for Src, Abl and all the resistant mutants.
(PNG)
S9 Fig. Principal component analysis. PCA analysis for Abl, Src and the resistant mutants of
Abl. The trajectories of Src and of the resistant mutants of Abl have been projected along the
first (hinge motion) and second (lobe twist) eigenvector of Abl.
(PDF)
S10 Fig. Structures describing the unbinding process of imatinib in T315I mutant. States D
and E corresponding to the alternative unbinding path of imatinib in the T315I mutant shown
in Fig 5 of the main text.
(PDF)
S11 Fig. Monodimensional profile of the free-energy convergence. Typical convergence of
the PTmetaD calculations. Projection of the free-energy of H396P along CV1 (distance
Asp404-Lys295) and of E450K along CV2 (distance Phe405-Ile293), calculated on the final 200
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ns of run, at intervals of 40 ns. The dotted lines correspond to the reweight performed on both
simulations.
(PNG)
S12 Fig. Diffusion of the collective variables in the PTmetaD simulations. Values of the
CVs used for the PTMetaD versus simulation time. In accordance with the behaviour expected,
the system diffuses freely in the CV space and visits all the basins within the threshold energy
multiple times.
(PDF)
S13 Fig. Free-energy profile of (un-)binding of imatinib in Abl WT.Monodimensional pro-
file of unbinding for Abl WT along the distance between the center of mass of residues
Asp404-Leu322-Val323 and Imatinib. The state C corresponds to the external binding pose of
Imatinib, while in state D imatinib is unbound and fully solvated.
(PDF)
S14 Fig. Free-energy surface convergence of G250E. Bidimensional profiles of G250E along
CV1 and CV2 calculated at intervals of 20 ns in the last 160 ns of simulation time. The very
small changes in the FES and the consistency of the relative ΔGs gives a good indication of the
sampling convergence.
(PDF)
S15 Fig. Free-energy surface convergence of T315I. Bidimensional profiles of T315I along
CV1 and CV2 calculated at intervals of 20 ns in the last 160 ns of simulation time.
(PDF)
S16 Fig. Free-energy surface convergence of E450K. Bidimensional profiles of E450K along
CV1 and CV2 calculated at intervals of 20 ns in the last 160 ns of simulation time.
(PDF)
S17 Fig. Free-energy surface convergence of H396P. Bidimensional profiles of H396P along
CV1 and CV2 calculated at intervals of 20 ns in the last 160 ns of simulation time.
(PDF)
S18 Fig. Free-energy surface convergence of E279K. Bidimensional profiles of E279K along
CV1 and CV2 calculated at intervals of 20 ns in the last 160 ns of simulation time.
(PDF)
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